Conny Börje Bogentoft
Direktor/Vorstandsmitglied bei Galenica AB
Ursprung des Netzwerks ersten Grades von Conny Börje Bogentoft
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Galenica AB
 Galenica AB Pharmaceuticals: MajorHealth Technology Galenica AB develops and manufactures pharmaceutical drugs. It offers service to partners for the development of oral, dermal, nasal, rectal, pulmonary and parenteral formulations of small molecules to peptides/proteins and biologics. The company was founded in 1999 and is headquartered in Malmo, Sweden.
8
| Private Company | Pharmaceuticals: Major | 8 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
8
| Operating Division | Investment Managers | 8 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Conny Börje Bogentoft
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Chief Investment Officer Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal | |
| KCIF Fund Management AB | Director/Board Member Chief Executive Officer Chief Executive Officer Chairman | ||
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
Volito AB
 Volito AB Financial ConglomeratesFinance Volito AB provides investment services. Its main activities are in the business areas of aviation, real estate, structured finance and industry. Volito was founded in 1991 and is headquartered in Malmö, Sweden. | Financial Conglomerates | Chief Executive Officer Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
EkoBalans Fenix AB
 EkoBalans Fenix AB Environmental ServicesIndustrial Services EkoBalans Fenix AB provide sewage treatment solutions. Its services include sewage treatment plants, biogas plants, and food producers. The firm provides solutions for the management of nutrient-rich waste products such as digestion residues and sludge. The company was founded by Gunnar Nicoulaus Thelin in 2008 and is headquartered in Lund, Sweden. | Environmental Services | Chairman Director/Board Member | |
| LIPIDOR AB | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| ASARINA PHARMA AB | Pharmaceuticals: Major | Director/Board Member Public Communications Contact | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| KD Incentive AB | Director/Board Member Chairman | ||
Medeon AB
 Medeon AB Miscellaneous Commercial ServicesCommercial Services Medeon AB is a life science research park located in Malmö, Sweden. The Swedish company offers various services such as incubation, office and conference spaces, and laboratory facilities to its partner companies. Medeon focuses on several areas of research, including diabetes, nanomedicine, and pharma development. The private company has a diverse range of partner companies, including Ascelia Pharma, Biora AB/Straumann, and Gordiamkey. The CEO of the company is Ulf G. Andersson. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Palette Life Sciences AB
 Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| NEOS AB | Medical Specialties | Chairman Director/Board Member | |
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Director/Board Member Director/Board Member | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Investment Managers | Founder Analyst-Equity | |
| Kabi Pharmacia | Corporate Officer/Principal | ||
AB Wilhelm Becker
 AB Wilhelm Becker Chemicals: SpecialtyProcess Industries AB Wilhelm Becker operates as a holding company with interests in chemical companies. It manufactures industrial coatings for metals and plastics, and products for surface treatment of wood. The company is headquartered in Hoganas, Sweden. | Chemicals: Specialty | Corporate Officer/Principal | |
Biochromix AB
 Biochromix AB Medical SpecialtiesHealth Technology BioChromix AB manufactures diagnostic products. It is a company in the life science arena that develops and commercializes products for early stage diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The firm’s methods are based on their novel and patented Luminescent Conjugated Polymer (LCP) molecules. The company is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member | |
| OSSDSIGN AB | Medical Specialties | Director/Board Member | |
| NANEXA AB | Medical Specialties | Corporate Officer/Principal | |
| Pharmor AB | Chief Executive Officer | ||
| Isles of Wines AB | Chief Executive Officer | ||
| ZICCUM AB | Medical Specialties | Corporate Officer/Principal | |
| Stockholm Biotechbuilders Association | Director/Board Member | ||
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Pharmaceuticals: Major | Director/Board Member | |
| XSPRAY PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Founder | |
| NEXTCELL PHARMA AB | Pharmaceuticals: Major | Founder | |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Chairman | |
Eribis Pharmaceuticals AB
 Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Pharmaceuticals: Major | Director/Board Member | |
| Biocelex Ltd. Oy | Director/Board Member | ||
Novozymes Biopharma Sweden AB
 Novozymes Biopharma Sweden AB BiotechnologyHealth Technology Part of Repligen Corp., Novozymes Biopharma Sweden AB operates as a contract manufacturer of biological products. The company is based in Lund, Sweden. The CEO of the Swedish company is Harald Skogman. Novozymes Biopharma Sweden was acquired by Repligen Corp. from Novozymes A/S on December 20, 2011 for $29.02 million. | Biotechnology | Corporate Officer/Principal | |
MarBiLeads AS
 MarBiLeads AS BiotechnologyHealth Technology MarBiLeads AS engages in the development of drug candidates for infections and cancer based on marine microorganisms. The company was founded on December 22, 2010 and is headquartered in Trondheim, Norway. | Biotechnology | Director/Board Member | |
| Ola Flink Consulting AB | Chairman | ||
| PROMIMIC AB | Medical Specialties | Director/Board Member | |
| Royal Institute of Technology | College/University | Graduate Degree |
Statistik
International
| Schweden | 45 |
| Norwegen | 3 |
| Finnland | 3 |
| Dänemark | 2 |
| Vereinigte Staaten | 2 |
Sektoral
| Health Technology | 31 |
| Commercial Services | 7 |
| Finance | 4 |
| Industrial Services | 2 |
| Process Industries | 2 |
Operativ
| Director/Board Member | 125 |
| Corporate Officer/Principal | 35 |
| Chairman | 34 |
| Chief Executive Officer | 25 |
| Independent Dir/Board Member | 16 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Conny Börje Bogentoft
- Unternehmensverbindungen
